BIOMAT Database Logo BIOMAT Database Logo

Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease. 1997

J A Molina, and F J Jiménez-Jiménez, and P Gomez, and C Vargas, and J A Navarro, and M Ortí-Pareja, and T Gasalla, and J Benito-León, and F Bermejo, and J Arenas
Department of Neurology, Hospital Doce de Octubre, Madrid, Spain.

We measured the CSF levels of 21, and the plasma levels of 26, amino acids in 31 patients with Parkinson's disease (PD) and in 45 matched controls. We used an ion-exchange chromatography method. When compared to controls, PD patients had lower CSF levels of taurine, alanine, valine, leucine, isoleucine, ethanolamine, citrulline, ornithine, lysine, histidine, arginine, and alpha-aminobutyric acid. PD patients not treated with levodopa or with dopamine agonists had higher CSF tyrosine and phenylalanine levels than those not treated with these drugs and also than controls. PD patients had higher plasma levels of phosphoserine, threonine, methionine, tyrosine, sarcosine and alpha-aminoadipic acid, and lower plasma levels of valine, leucine, and tryptophan, than controls. The CSF/plasma ratio of many of these amino acids was significantly lower in PD patients than those of controls, suggesting that PD patients might have a dysfunction in the transport of neutral and basic amino acids across the blood-brain barrier.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000596 Amino Acids Organic compounds that generally contain an amino (-NH2) and a carboxyl (-COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins. Amino Acid,Acid, Amino,Acids, Amino
D000978 Antiparkinson Agents Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. Antiparkinson Drugs,Antiparkinsonian Agents,Antiparkinsonians,Agents, Antiparkinson,Agents, Antiparkinsonian,Drugs, Antiparkinson

Related Publications

J A Molina, and F J Jiménez-Jiménez, and P Gomez, and C Vargas, and J A Navarro, and M Ortí-Pareja, and T Gasalla, and J Benito-León, and F Bermejo, and J Arenas
Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease.
August 2003, Neurochemical research,
J A Molina, and F J Jiménez-Jiménez, and P Gomez, and C Vargas, and J A Navarro, and M Ortí-Pareja, and T Gasalla, and J Benito-León, and F Bermejo, and J Arenas
Cerebrospinal fluid choline levels are decreased in Parkinson's disease.
June 1990, Annals of neurology,
J A Molina, and F J Jiménez-Jiménez, and P Gomez, and C Vargas, and J A Navarro, and M Ortí-Pareja, and T Gasalla, and J Benito-León, and F Bermejo, and J Arenas
Alteration of amino acids in cerebrospinal fluid from patients with Parkinson's disease and spinocerebellar degeneration.
February 1986, Acta neurologica Scandinavica,
J A Molina, and F J Jiménez-Jiménez, and P Gomez, and C Vargas, and J A Navarro, and M Ortí-Pareja, and T Gasalla, and J Benito-León, and F Bermejo, and J Arenas
[Free amino acids in blood and cerebrospinal fluid in Parkinson's disease].
July 1953, Minerva medica,
J A Molina, and F J Jiménez-Jiménez, and P Gomez, and C Vargas, and J A Navarro, and M Ortí-Pareja, and T Gasalla, and J Benito-León, and F Bermejo, and J Arenas
Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patients.
January 1994, Journal of the neurological sciences,
J A Molina, and F J Jiménez-Jiménez, and P Gomez, and C Vargas, and J A Navarro, and M Ortí-Pareja, and T Gasalla, and J Benito-León, and F Bermejo, and J Arenas
Changes in the concentration of amino acids in serum and cerebrospinal fluid of patients with Parkinson's disease.
October 1997, Journal of the neurological sciences,
J A Molina, and F J Jiménez-Jiménez, and P Gomez, and C Vargas, and J A Navarro, and M Ortí-Pareja, and T Gasalla, and J Benito-León, and F Bermejo, and J Arenas
Transport of neutral amino acids from feline cerebrospinal fluid.
October 1969, The American journal of physiology,
J A Molina, and F J Jiménez-Jiménez, and P Gomez, and C Vargas, and J A Navarro, and M Ortí-Pareja, and T Gasalla, and J Benito-León, and F Bermejo, and J Arenas
Cerebrospinal fluid levels of neuropeptides, cortisol, and amino acids in patients with epilepsy.
January 1993, Epilepsia,
J A Molina, and F J Jiménez-Jiménez, and P Gomez, and C Vargas, and J A Navarro, and M Ortí-Pareja, and T Gasalla, and J Benito-León, and F Bermejo, and J Arenas
Decreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer's Disease.
January 2018, Frontiers in neuroscience,
J A Molina, and F J Jiménez-Jiménez, and P Gomez, and C Vargas, and J A Navarro, and M Ortí-Pareja, and T Gasalla, and J Benito-León, and F Bermejo, and J Arenas
[Cerebrospinal fluid amino acids in Alzheimer's disease].
January 1990, Annales de biologie clinique,
Copied contents to your clipboard!